May 13, 2024

BioTissue’s Advanced Wound Care Solutions Take Center Stage at SAWC Spring

Neox®1K Human Amniotic Membrane Derived from Umbilical Cord Allografts Highlighted in Clinical Case Studies Demonstrating Effectiveness in Managing Diabetic Ulcers, Necrotizing Fasciitis, and Traumatic Wounds

MIAMI, May 13, 2024—During this week’s Symposium on Advanced Wound Care (SAWC) Spring meeting in Orlando, clinical researchers will showcase posters summarizing three case studies that illustrate the efficacy of BioTissue’s Neox®1K human amniotic membrane allografts in the management of necrotizing fasciitis, diabetic ulcers, and complex post-traumatic wounds. BioTissue leads the way in the application of cryopreserved human birth tissue products for regenerative healing of chronic wounds, musculoskeletal conditions, and ocular surface disease and disorders.

“We are excited to spotlight BioTissue’s dedication to transforming wound care with cutting-edge solutions like Neox® 1K amniotic membrane allografts at SAWC Spring,” said BioTissue’s CEO Ted Davis. “This new research underscores its promise in managing complex wounds, ultimately enhancing patient outcomes and helping patients return to the life they love.”

The following three posters featuring BioTissue’s Neox® 1K Cryopreserved Amniotic Membrane (CAM) allografts will be available for viewing at SAWC:

  • Use of Ultra-Thick Cryopreserved Amniotic Membrane Allograft in the Management of Necrotizing Fasciitis

Christopher Stewart, MD, Little Rock, AR

Necrotizing Fasciitis (NF) is a severe soft-tissue infection with mortality rates up to 35%, often requiring surgical debridement. Cryopreserved Amniotic Membrane (CAM) is increasingly used in wound management due to its regenerative properties. In a recent case, a 62-year-old female with NF on her left arm was successfully treated with an ultra-thick CAM allograft after multiple surgical debridements. Within six weeks, complete wound closure and functional recovery were achieved, highlighting the efficacy of CAM allografts in NF-related, deep cavity wounds.

  • Use of Ultra-Thick Cryopreserved Amniotic Membrane Allograft in the Wound Management of an Open Humerus Fracture

Christopher Stewart, MD, Little Rock, AR

The management of distal humerus fractures poses significant challenges, often leading to post-operative complications such as delayed wound healing. In this study, a 34-year-old female with an open humerus fracture from a motor vehicle accident was successfully treated with an ultra-thick CAM allograft. Following open reduction and internal fixation, she received CAM application, leading to robust tissue regeneration and rapid wound closure. Complete healing with minimal scarring was achieved by eight weeks, demonstrating the efficacy of ultra-thick CAM allografts in managing traumatic wounds.

  • Ultra-Thick Cryopreserved Amniotic Membrane Allograft and Disposable Negative Pressure Wound Therapy in the Management of an Ischemic, Diabetic Ulcer

David Fernandez, MD, Orlando, FL

Lower extremity ulceration is a prevalent and challenging condition affecting millions worldwide, particularly the elderly and those with peripheral vascular disease. This case follows a 57-year-old woman with a lateral malleolar wound, complicated by diabetes, peripheral vascular disease, and chronic smoking, who was successfully treated with an ultra-thick CAM allograft and disposable Negative Pressure Wound Therapy (NPWT). Despite multiple risk factors, significant progress was observed within weeks of treatment initiation, highlighting the effectiveness of combining these therapies to facilitate wound closure in complex scenarios.

Dr. Stewart’s and Dr. Fernandez’s posters, entries CS-147, CS-146, and CS-056, respectively, will be featured at the live poster reception on May 16th 7:30pm – 8:30pm and will be on display 7:30 AM – 5:00 PM throughout the conference, which takes place May 14 – 18 at the Orlando World Center Marriott. Visit SAWC Spring’s Abstract Page for more information.

# # #

†Neox® 1K; BioTissue, Miami, FL

About BioTissue Holdings Inc.

BioTissue is an emerging biotechnology company and leader in harnessing the unique power of human birth tissue to support regenerative healing for ocular surface disease and in surgical, chronic wound, and musculoskeletal applications. BioTissue’s portfolio of cryopreserved amniotic membrane products use its proprietary CryoTek® cryopreservation technology, designed to retain the tissue’s structural and functional integrity. The company continues to break new ground with multiple Investigational New Drug (IND) clinical trials as the company pursues Biologic License Applications (BLAs) for products to treat patients’ unmet clinical needs. BioTissue is committed to empowering healthcare professionals with solutions to deliver optimal patient outcomes by fostering innovation through evidence-based science. Since its inception, clinicians have performed over 800,000 human implants with its products and published over 390 peer-reviewed studies supporting BioTissue’s platform technology. Learn more at

Media Contact

Laura DiCaprio

McDougall Communications for BioTissue

[email protected] or (585) 434-2153


Related Content